⌘K
Loading ticker…
As of 2026-08-24, Exelixis Inc (EXEL) has a 3-month relative strength percentile of 65 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 56. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 3.4%, relative volume 0.88×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
EXEL is in a stage 2 uptrend, week 1. Currently in a 32-day base; basing ADR 2.9% (broad 3.1%). VCP detected: no. RS line below base-start high. Distance from 50d / 200d: 0.5% / 16.1%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
EXEL is held by 68 ETFs as of May 2026. Top owner: VHT at 0.20% weight, $39M notional. Top 3 carry $108M.
Held by 210 ETFs · $2.7B across latest filings · largest weight 3.80% (IDNA).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VHTVanguard Health Care ETF | 0.20% | $39M | +0.04 pp |
| SCHMSchwab U.S. Mid-Cap ETF | 0.24% | $35M | — |
| AVLVAvantis U.S. Large Cap Value ETF | 0.26% | $34M | +0.04 pp |
| IVOO | 0.37% | $21M | +0.03 pp |
| FNDA | 0.20% |
Attention is elevated versus its own recent norm without the relative strength to match — the loud-but-lagging pattern. Worth a skeptical eye; not a short signal.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| $18M |
| +0.04 pp |
| VONGVanguard Russell 1000 Growth ETF | 0.03% | $18M | — |
| OMFL | 0.30% | $14M | +0.25 pp |
| SCHXSchwab U.S. Large-Cap ETF | 0.02% | $14M | — |
| IVOG | 0.72% | $13M | +0.06 pp |
| QGRO | 0.58% | $13M | +0.05 pp |
Showing 10 of 68 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EXEL Jan avg: -1.38% median: -3.04% win: 25% σ: 8.32% n: 4 2022-04-12 → 2026-07-31 | EXEL Feb avg: 5.21% median: 3.59% win: 75% σ: 8.63% n: 4 2022-04-12 → 2026-07-31 | EXEL Mar avg: 3.69% median: 2.85% win: 50% σ: 8.74% n: 4 2022-04-12 → 2026-07-31 | EXEL Apr avg: 0.52% median: -0.22% win: 40% σ: 4.54% n: 5 2022-04-12 → 2026-07-31 | EXEL May avg: 0.67% median: 5.36% win: 60% σ: 13.11% n: 5 2022-04-12 → 2026-07-31 | EXEL Jun avg: 5.30% median: 3.60% win: 80% σ: 5.58% n: 5 2022-04-12 → 2026-07-31 | EXEL Jul avg: -2.48% median: 0.48% win: 60% σ: 8.98% n: 5 2022-04-12 → 2026-07-31 | EXEL Aug avg: 3.18% median: 7.16% win: 75% σ: 13.01% n: 4 2022-04-12 → 2026-07-31 (current) | EXEL Sep avg: -0.99% median: -1.36% win: 25% σ: 9.03% n: 4 2022-04-12 → 2026-07-31 | EXEL Oct avg: 5.39% median: -0.01% win: 50% σ: 16.03% n: 4 2022-04-12 → 2026-07-31 | EXEL Nov avg: 8.25% median: 7.87% win: 100% σ: 4.86% n: 4 2022-04-12 → 2026-07-31 | EXEL Dec avg: -1.38% median: -3.43% win: 25% σ: 8.27% n: 4 2022-04-12 → 2026-07-31 |